Familial Nasopharyngeal Carcinoma 6

Subject Index 329Thyroid hormone replacement treatment, 238Thyroid-stimulating hormone (TSH), 234Thyroxine, 238Tinnitus, 60Tissue hypoxia, 282TKI. See Tyrosine kinase inhibitorsTNM staging system, 96, 309Tomotherapy, 248Torus tubarius, 214Toxicity, 169Transcervical approach. See NasopharyngectomyTransforming growth factor-a (TGF-a), 29Transmaxillary approach. See NasopharyngectomyTranspalatal approach. See NasopharyngectomyTreatment failures, 128Trismus, 43Trotter’s syndrome, 44Tumor-associated tissue eosinophilia (TATE), 114Tumor marker, 103Tumor necrosis factor receptor (TNFR), 16Tumor regression, 127Tumor suppressor genes, 11Tumor volume, 97, 319Tympanic membrane, 280Tympanometry, 281Tyrosine kinase inhibitor gefitinib, 272Tyrosine kinase inhibitors (TKI), 32, 177UUFT, 172, 175Undifferentiated carcinoma (UC), 10, 72Union Against Cancer (UICC) staging, 96VEGF receptors (VEGFR), 34Villaret syndrome. See Syndrome of the retroparotidspace of VillaretVinca alkaloids, 153Vincristine, 194Vincristine, bleomycin, and methotrexate, (VBM), 172Vinorelbine, 153Viral capsid antigen (VCA), 4, 54, 68, 237Viral microRNAs (miRNAs), 16Vitamin E, 282WWeight loss, 117–118, 305WHO. See World Health OrganizationWnt/b-catenin pathway. See Cellular signaling pathwaysWnt inhibitory factor (WIF), 36Wnt signaling pathway, 36World Health Organization (WHO), 104, 118World Health Organization Classification, 10, 53XXerostomia, 208, 276–280, 305ZZygomatic arch, 317VVAC, 301Vascular endothelial growth factor (VEGF), 33, 114,156, 177VCA-IgA, 106